Revolutionizing Diabetes and Obesity Care

The global rise in Type 2 diabetes and obesity has spurred a growing demand for innovative health solutions, particularly GLP-1, GGG, and GIPR agonists. Our Forecast projections indicate that the GLP-1 market could reach $70 billion by 2030, underscoring the need for innovative supply and manufacturing solutions. Despite the MENA region's GLP-1 market featuring lower-end pricing, it remains attractive due to high diabetes and obesity prevalence, with Saudi Arabia securing a significant 35% market share. Currently, there are 105 products in the pipeline for GLP-1, GGG, GIPR agonists, with companies like Novo Nordisk, Zealand Pharma, Eli Lilly and Company, and Gmax Bio pharm leading the way in substantial pipelines for these health solutions.